What are the compliance requirements for sequence listings in patent applications?
According to MPEP 2422.07, patent applications must comply with the requirements of 37 CFR 1.821(b) through (e) for sequence listings. The section states: “37 CFR 1.821(g) requires compliance with the requirements of 37 CFR 1.821(b) through (e) , as discussed above, if they are not satisfied at the time of filing under 35 U.S.C. 111(a)…
Read MoreWhen must amino acid sequences be set forth separately in a patent application?
According to the MPEP, amino acid sequences must be set forth separately under certain conditions. Specifically: “When the coding parts of a nucleotide sequence and their corresponding amino acids have been enumerated by their residues, those amino acids must also be set forth as a separate sequence if the amino acid sequence meets the length…
Read MoreWhat are the requirements for international applications disclosing nucleic acid or amino acid sequences?
For international applications subject to WIPO ST.25 requirements that disclose nucleic acid or amino acid sequences, specific rules apply. MPEP 2420 states: “See PCT Rule 5 and Rule 13ter, and MPEP § 1823.02 and § 2422, for the requirements under the PCT for international applications subject to WIPO ST.25 requirements and that disclose nucleic acid…
Read MoreHow are codons that span introns represented in sequence listings?
The MPEP addresses the representation of codons that span introns in 37 CFR 1.822(c)(3). Specifically, it states: “In those situations, the ‘amino acid symbol shall be listed below the portion of the codon containing two nucleotides.’” This requirement clarifies how to represent an amino acid corresponding to a codon that spans an intron. It ensures…
Read MoreWhat should I include in a statement for replacing a sequence listing?
When replacing a sequence listing in a patent application, the MPEP provides guidance on what to include in your statement. The sample statement covers three key points: Identifying changes to the previous sequence listing Asserting support in the original application Declaring no new matter has been added Here’s the sample statement from the MPEP: “I…
Read MoreWhat is PSIPS and how is it related to Sequence Listings?
PSIPS stands for Publication Site for Issued and Published Sequences. It is a platform used by the USPTO for publishing lengthy Sequence Listings separately from the main patent document. MPEP 2419.02 states: “Any ASCII text file produced by the USPTO that is 600KB or more, but under 1GB will be processed for separate publication on…
Read MoreWhat is PatentIn and how does it relate to sequence listings?
PatentIn is a software program developed by the USPTO to facilitate compliance with sequence rules for patent applications involving nucleotide and amino acid sequences. It helps applicants generate sequence listings in a format compliant with 37 CFR 1.821-1.825 and WIPO Standard ST.25. The MPEP states: While use of the PatentIn program is not required for…
Read MoreWhat are the standard single-letter codes for modified and unusual nucleotides in WIPO ST.25?
What are the standard single-letter codes for modified and unusual nucleotides in WIPO ST.25? WIPO ST.25 provides standard single-letter codes for modified and unusual nucleotides in sequence listings. According to MPEP 2423: “The nucleotides listed in Appendix 2, Table 2, are the only permitted nucleotides. Where a sequence includes “other” nucleotides, they must be represented…
Read MoreWhat are the accepted symbols for modified nucleotides in sequence listings?
What are the accepted symbols for modified nucleotides in sequence listings? According to MPEP 2412.05, modified nucleotides can be represented in sequence listings using specific symbols. The MPEP states: “Modified nucleotides may be represented in the sequences as described in paragraph 3 of this section with the symbol “n,” and must be further described in…
Read MoreWhat are the rules for representing modified amino acids in WIPO ST.25 sequence listings?
What are the rules for representing modified amino acids in WIPO ST.25 sequence listings? The representation of modified amino acids in WIPO ST.25 sequence listings follows specific rules as outlined in MPEP 2423: “Modified amino acids must be represented as the corresponding unmodified amino acids in the sequence itself if possible. Any modified amino acids…
Read More